NTRA
Natera Inc
$328.18+0.16%
Setup
Near pivot
Buy Zone
$323.01-$339.16
Sector
Diagnostics & Research
Industry
Diagnostics & Research
69
Recommendation
Watch
Watch
Interesting but not enough buy criteria met yet.
NTRA chart
Loading chart…
Overall Quality69
RS Rating
90
relative strength
Fundamentals
49
Weak fund-Q
Volume Demand
82
-30% vs avg
Technical Setup
88
7/8 checks
Industry/Theme
91
Diagnostics & Research
Trade Plan
Watch
Entry
$323.01
Entry Zone
$323.01-$339.16
Stop / Risk
$297.17
RS Rating
90
Volume confirmed
Yes
Targets
$387.61 / $403.76
Breakout · IBD Setup
7 ✓ 1 ✗
Entry $323.01–$339.16Stop $297.17Target $387.61 / $403.76
Market regimeUptrend
Quality69
RS Rating90
Above 50-MA+12.29%
Above 200-MA+39.27%
VolumeConfirmed
In Buy ZoneYes
Not extendedOK
Invalidation · Close below stop
How this came together
69
MarketUptrend
SetupNear pivot
ConfidenceExperimental · not backtested
Fund-Q49 · Weak
StatusWatch
Stock Data
52-Week Range157 – 343
Price % Chg YTD43.25%
Price % Chg 4wk23.66%
50-Day Avg Vol1.4 Mil
P/E Ratio—
Market Cap$47B
SectorHealthcare
IndustryDiagnostics & Research
Company Fundamentals
EPS % Chg (Qtr)36.85%
Sales % Chg (Qtr)37.71%
EPS Growth 5y11.7%
Sales Growth 5y42.61%
Annual ROE-12.54%
Gross Margin64.74%
Operating Margin-10.56%
Net Margin-7.11%
Debt / Equity0.13
Setup levels
Current price
$328.18
Pivot
$323.01
Distance to buy
-4.4%
52-week range
157.42-343.18
Trigger evidence
No active trigger evidence available.
Financial health checks
3/5
Return on equity above 15%
ROE -12.54%
Net margin above 10%
Net margin -7.11%
EPS growing quarter on quarter
EPS q/q 36.85%
Sales growing quarter on quarter
Sales q/q 37.71%
Debt to equity below 1.0
D/E 0.13
Key metrics
Finviz snapshot · value vs. sector median (≥5 peers)
Annual ROE-12.54%
vs sector -34.6%
Net margin-7.11%
vs sector -24.1%
Gross margin64.74%
vs sector -1.9%
EPS growth q/q36.85%
vs sector +28.8%
Sales growth q/q37.71%
vs sector +19.2%
Debt / equity0.13
vs sector -0.51
Business quality
49
GradeWeak
EPS rating59
P/E—
Market cap$47B
IndustryDiagnostics & Research
Technical checks
Über 50-MA
Pass
Über 200-MA
Pass
RS-Linie auf neuem Hoch
Fail
Volumen bestätigt
Pass
In Kaufzone
Pass
Nicht überextended
Pass
Über 21-EMA
Pass
Volumen gesund
Pass
IBD / source mentions
No recent IBD mention found for this ticker.
Signal history
Added to list
2026-08-30
Trigger date
—
Days on list
8
Data sources: internal CANSLIM engine · Finviz snapshot · TradingView chart. Not investment advice.